Taxane analogs for the treatment of brain cancer
AssigneeTapestry Pharmaceuticals, Inc.
InventorsJames D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
Claims20
A method of treating brain cancer in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a compound of Formula (1):
- wherein the compound of Formula (1) is administered as a unit dose comprising between 14 mg and 1000 mg of the compound of Formula (1).
A method of treating brain cancer in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a compound of Formula (1):
- wherein the therapeutically effective amount results in an in vivo plasma profile for the compound of Formula (1) in the mammal that includes a mean area under the curve from dosing time 0 to twenty-four hours (AUC0-24) of about 457 to 7,260 h*ng/mL.
Dependencies are inferred from the claim text.